

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Hong Liu Examiner #: 77011 Date: 8/11/03
 Art Unit: 1624 Phone Number 306-5814 Serial Number: 101043-627
 Mail Box and Bldg/Room Location: 4601 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.


Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: 8/1/03


For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Barb please!

RECEIVED
AUG 11 2003

B is a five or six membered, monocyclic, saturated heterocyclic ring.

elected species:



STAFF USE ONLY

Searcher: POB

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: 8-14-03Searcher Prep & Review Time: 20

Clerical Prep Time: _____

Online Time: 6

Type of Search

NA Sequence (#) _____

AA Sequence (#) _____

Structure (#) 2

Bibliographic _____

Litigation _____

Fulltext _____

Patent Family _____

Other _____

Vendors and cost where applicable

STN 190

Dialog _____

Questel/Orbit _____

Dr.Link _____

Lexis/Nexis _____

Sequence Systems _____

WWW/Internet _____

Other (specify) _____

THIS PAGE BLANK (USPTO)



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 100866

TO: Hong Liu
Location: CM-1/4E01/4E12
Art Unit: 1624
Thursday, August 14, 2003

Case Serial Number: 10/043627

From: Barb O'Bryen
Location: Biotech-Chem Library
CM1-6A05
Phone: 308-4291 *BOB*

barbara.obryen@uspto.gov

Search Notes

THIS PAGE BLANK (USPTO)



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact:*

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 - Circ. Desk



THIS PAGE BLANK (USPTO)

=> fil reg; d stat que 14; fil capl; d que nos 15; fil uspatf; d que nos 16; dup rem 15,16
 FILE 'REGISTRY' ENTERED AT 14:50:36 ON 14 AUG 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 13 AUG 2003 HIGHEST RN 566135-25-9
 DICTIONARY FILE UPDATES: 13 AUG 2003 HIGHEST RN 566135-25-9


TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
 PROPERTIES for more information. See STNote 27, Searching Properties
 in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1 STR



Hy = heterocycle
Cb = carbocycle
Q = any atom other than H or C

VAR G1=7/10/13/15

VAR G2=O/S/N/18

NODE ATTRIBUTES:

NSPEC IS RC AT 2

CONNECT IS E2 RC AT 7

CONNECT IS E2 RC AT 15

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY SAT AT 1

GGCAT IS PCY LOQ UNS AT 9

GGCAT IS PCY LOQ UNS AT 11

GGCAT IS PCY LOQ UNS AT 14

GGCAT IS PCY LOQ UNS AT 16

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS X5 C AT 1

ECOUNT IS E9 C E1 N AT 9

ECOUNT IS E9 C E1 N AT 11

ECOUNT IS E9 C E1 N AT 14

ECOUNT IS E9 C E1 N AT 16

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L2 STR

*heterocycle at node 1 is monocyclic,
 saturated, & has a maximum of 5 carbons*
*heterocycles at nodes 9, 11, 14, 16 are
 polycyclic, unsaturated, with 1 nitrogen &
 9 carbons*



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L4 212 SEA FILE=REGISTRY SSS FUL L1 AND L2

100.0% PROCESSED 48507 ITERATIONS

212 ANSWERS

SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 14:50:36 ON 14 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Aug 2003 VOL 139 ISS 7

FILE LAST UPDATED: 13 Aug 2003 (20030813/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 STR
L2 STR
L4 212 SEA FILE=REGISTRY SSS FUL L1 AND L2
L5 3 SEA FILE=CAPLUS ABB=ON L4

FILE 'USPATFULL' ENTERED AT 14:50:36 ON 14 AUG 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 14 Aug 2003 (20030814/PD)

FILE LAST UPDATED: 14 Aug 2003 (20030814/ED)

HIGHEST GRANTED PATENT NUMBER: US6606748

HIGHEST APPLICATION PUBLICATION NUMBER: US2003154532
CA INDEXING IS CURRENT THROUGH 14 Aug 2003 (20030814/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 14 Aug 2003 (20030814/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L1 STR
L2 STR
L4 212 SEA FILE=REGISTRY SSS FUL L1 AND L2
L6 3 SEA FILE=USPATFULL ABB=ON L4

FILE 'CAPLUS' ENTERED AT 14:50:36 ON 14 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)



FILE 'USPATFULL' ENTERED AT 14:50:36 ON 14 AUG 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L5
PROCESSING COMPLETED FOR L6
L8 6 DUP REM L5 L6 (0 DUPLICATES REMOVED)
ANSWERS '1-3' FROM FILE CAPLUS
ANSWERS '4-6' FROM FILE USPATFULL

=> d ibib abs hitstr 1-6; fil cao;d que nos 17; fil hom

L8 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:539676 CAPLUS
DOCUMENT NUMBER: 137:93693
TITLE: Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-
substituted pyrrolidineacetamides and
piperidineacetamides and related compounds as MMP,
TNF, and/or aggreganase inhibitors
INVENTOR(S): Chen, Xiao-Tao; Xue, Chu-Biao
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055516	A2	20020718	WO 2002-US761	20020109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002137734	A1	20020926	US 2002-43627	20020109
PRIORITY APPLN. INFO.:		US 2001-260952P P 20010111		
OTHER SOURCE(S):		MARPAT 137:93693		
GI				



AB Title compds. I [wherein A = COR5, CO2H, CH2CO2H, CO2R6, CONHOH, CONHOR5, CONHOR6, N(OH)CHO, N(OH)COR5, SH, CH2SH, SONHRa, SN2H2Ra, PO3H2, or PO(OH)NHRa; ring B = 3-10 membered (hetero)cycle; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl),, CO, CO2, OCO, CONH, NHCO, OCO2, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SO0-2, or CO; Za = (un)substituted (hetero)cyclyl; R1a and R1b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR1aR1b = (hetero)cyclyl; R2 = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; R2a and R2b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR2aR2b = heterocyclyl; R3 = Q1 or (un)substituted alkylene-Q1,


alkenylene-Q1, or alkynylene-Q1, Q1-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R3)2 = (un)substituted (hetero)cyclyl; Q1 = H or (un)substituted Ph, naphthyl, or heteroaryl; Ra = H, alkyl, Ph, or PhCH2; p = 0-2; R5 = (un)substituted alkyl; R6 = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepd. as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the N-hydroxy-2-(quinolinylmethoxyphenylsulfonylmethyl)-2-pyrrolidineacetamide II.bul.2CF3CO2H was prepd. in twelve steps starting with the esterification of N-Boc-proline using MeI and K2CO3 in acetone. Key steps include the addn. of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline.bul.HCl. A no. of invention compds. exhibited Ki values of .ltoreq. 10 .mu.M against MMP-1, 2, 3; 9, and 13. Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).

IT 441772-86-7P 441772-87-8P 441772-88-9P
441772-89-0P 441772-90-3P 441772-91-4P
441772-92-5P 441772-93-6P 441772-94-7P
441772-95-8P 441772-96-9P 441772-97-0P
441772-98-1P 441772-99-2P 441773-00-8P
441773-01-9P 441773-02-0P 441773-03-1P
441773-04-2P 441773-05-3P 441773-06-4P
441773-07-5P 441773-08-6P 441773-09-7P
441773-11-1P 441773-12-2P 441773-13-3P
441773-14-4P 441773-15-5P 441773-16-6P
441773-17-7P 441773-18-8P 441773-19-9P
441773-20-2P 441773-21-3P 441773-22-4P
441773-23-5P 441773-24-6P 441773-25-7P
441773-26-8P 441773-27-9P 441773-28-0P
441773-29-1P 441773-30-4P 441773-31-5P
441773-42-8P 441773-43-9P 441773-44-0P
441773-45-1P 441773-52-0P 441773-53-1P
441773-54-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MMP, TNF, and/or aggrecanase inhibitor; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidineacetamides and piperidineacetamides and related compds. as MMP, TNF, and/or aggrecanase inhibitors)

RN 441772-86-7 CAPLUS
CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441772-87-8 CAPLUS

CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-86-7


CMF C24 H27 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-88-9 CAPLUS

CN 2-Pyrrolidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441772-89-0 CAPLUS

CN 2-Pyrrolidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-88-9


CMF C25 H29 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-90-3 CAPLUS


CN 2-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441772-91-4 CAPLUS
CN 2-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441772-90-3
CMF C28 H35 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 441772-92-5 CAPLUS

CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 441772-93-6 CAPLUS

CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-92-5


CMF C29 H30 N4 O5 S



CM 2.


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-94-7 CAPLUS


CN 2-Pyrrolidineacetamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441772-95-8 CAPLUS
CN 2-Pyrrolidineacetamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyloxy)methoxy]phenyl]sulfonyl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441772-94-7
CMF C26 H29 N3 O6 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 441772-96-9 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441772-97-0 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-96-9


CMF C24 H27 N3 O5 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441772-98-1 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


/Me

RN 441772-99-2 CAPLUS
CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 441772-98-1
CMF C25 H29 N3 O5 S

PAGE 1-A



PAGE 2-A


/

Me

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-00-8 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


i-Pr

RN 441773-01-9 CAPLUS
CN 3-Pyrrolidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-00-8
CMF C27 H33 N3 O5 S

PAGE 1-A



PAGE 2-A


/

i-Pr

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-02-0 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


i-Bu

RN 441773-03-1 CAPLUS
CN 3-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-02-0
CMF C28 H35 N3 O5 S


PAGE 1-A




PAGE 2-A

/
 i-Bu


CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 441773-04-2 CAPLUS
CN 3-Pyrrolidineacetamide, 1-(2,2-dimethylpropyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 441773-05-3 CAPLUS
CN 3-Pyrrolidineacetamide, 1-(2,2-dimethylpropyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441773-04-2
CMF C29 H37 N3 O5 S

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-06-4 CAPLUS


CN 2-Piperidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-07-5 CAPLUS
CN 2-Piperidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441773-06-4
CMF C25 H29 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-08-6 CAPLUS
CN 2-Piperidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-09-7 CAPLUS
CN 2-Piperidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-08-6
CMF C26 H31 N3 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441773-11-1 CAPLUS

CN 2-Piperidineacetamide, N-hydroxy-1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-10-0


CMF C29 H37 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-12-2 CAPLUS

CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-13-3 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-12-2

CMF C25 H29 N3 O4 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-14-4 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-15-5 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441773-14-4
CMF C26 H31 N3 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 441773-16-6 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-17-7 CAPLUS

CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, bis(trifluoroacetate) (salt)
(9CI) (CA INDEX NAME)

CM 1


CRN 441773-16-6

CMF C28 H35 N3 O4 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-18-8 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-19-9 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-18-8
CMF C25 H29 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-20-2 CAPLUS


CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-21-3 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441773-20-2
CMF C26 H31 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-22-4 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-23-5 CAPLUS
CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-22-4
CMF C28 H35 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-24-6 CAPLUS

CN 3-Piperidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-25-7 CAPLUS

CN 3-Piperidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-24-6

CMF C29 H37 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-26-8 CAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-27-9 CAPLUS
CN 4-Piperidineacetamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-26-8
CMF C25 H29 N3 O5 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-28-0 CAPLUS

CN 4-Piperidineacetamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


Me

RN 441773-29-1 CAPLUS
CN 4-Piperidineacetamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 441773-28-0
CMF C26 H31 N3 O5 S

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 441773-30-4 CAPLUS
 CN 2-Furanacetamide, tetrahydro-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-31-5 CAPLUS
CN 2-Furanacetamide, tetrahydro-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441773-30-4
CMF C24 H26 N2 O6 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-42-8 CAPLUS
CN 3-Oxetaneacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-43-9 CAPLUS
CN 3-Oxetaneacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-42-8
CMF C23 H24 N2 O6 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-44-0 CAPLUS

CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 441773-45-1 CAPLUS


CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-44-0

CMF C25 H27 N3 O6 S

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-52-0 CAPLUS


CN 2H-Pyran-4-acetamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-53-1 CAPLUS
CN 2H-Pyran-4-acetamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyloxy)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441773-52-0
CMF C25 H28 N2 O6 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 441773-54-2 CAPLUS
CN 2-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




IT 441773-57-5P 441773-58-6P 441773-59-7P
441773-60-0P 441773-61-1P 441773-62-2P
441773-63-3P 441773-64-4P 441773-65-5P
441773-66-6P 441773-74-6P 441773-75-7P
441773-77-9P 441773-79-1P 441773-80-4P
441773-81-5P 441773-85-9P 441773-86-0P
441773-87-1P 441773-88-2P 441773-89-3P
441773-90-6P 441773-91-7P 441773-92-8P
441773-96-2P 441773-97-3P 441773-98-4P
441773-99-5P 441774-00-1P 441774-01-2P
441774-02-3P 441774-03-4P 441774-04-5P
441774-05-6P 441774-06-7P 441774-08-9P
441774-13-6P 441774-14-7P 441774-15-8P
441774-16-9P 441774-20-5P 441774-21-6P
441774-22-7P 441774-23-8P 441774-24-9P
441774-47-6P 441774-48-7P 441774-52-3P
441774-53-4P 441774-54-5P 441774-55-6P
441774-56-7P 441774-75-0P 441774-76-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidineacetamides and piperidineacetamides and related compds. as MMP, TNF, and/or aggrecanase inhibitors)


RN 441773-57-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-2-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-58-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-59-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-60-0 CAPLUS

CN 2-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-61-1 CAPLUS


CN 2-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441773-62-2 CAPLUS
CN 2-Pyrrolidineacetic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-63-3 CAPLUS
CN 2-Pyrrolidineacetic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-64-4 CAPLUS

CN 2-Pyrrolidineacetic acid, 1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-65-5 CAPLUS

CN 2-Pyrrolidineacetic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 441773-66-6 CAPLUS


CN 2-Pyrrolidineacetic acid, 1-acetyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-74-6 CAPLUS

CN 3-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-75-7 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 441773-77-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolyl)methoxy]phenyl]sulfonyl]methyl]-ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-76-8
CMF C27 H32 N2 O5 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 441773-79-1 CAPLUS


CN 3-Pyrrolidineacetic acid, 1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-78-0

CMF C29 H36 N2 O5 S


PAGE 1-A



PAGE 2-A


/
i-Pr

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 441773-80-4 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


/
i-Bu

RN 441773-81-5 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-(2,2-dimethylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 441773-85-9 CAPLUS
CN Quinoline, 2-methyl-4-[[4-[[[2-(2-propenyl)-2-piperidinyl]methyl]thio]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 441773-86-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-2-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-87-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-88-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-89-3 CAPLUS

CN 2-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-90-6 CAPLUS


CN 2-Piperidineacetic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441773-91-7 CAPLUS

CN 2-Piperidineacetic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441773-92-8 CAPLUS


CN 2-Piperidineacetic acid, 1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-96-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-3-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-97-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-3-(2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-98-4 CAPLUS
CN 3-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-99-5 CAPLUS
CN 3-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI)
(CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 441774-00-1 CAPLUS
CN 3-Piperidineacetic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-01-2 CAPLUS
CN 3-Piperidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-02-3 CAPLUS
CN 3-Piperidineacetic acid, 1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-03-4 CAPLUS

CN 3-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441774-04-5 CAPLUS

CN 3-Piperidineacetic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-05-6 CAPLUS

CN 3-Piperidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-06-7 CAPLUS

CN 3-Piperidineacetic acid, 1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-08-9 CAPLUS

CN 3-Piperidineacetic acid, 1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-13-6 CAPLUS
CN 4-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441774-14-7 CAPLUS
CN 4-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 441774-15-8 CAPLUS
CN 4-Piperidineacetic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-16-9 CAPLUS
CN 4-Piperidineacetic acid, 1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

|
Me

RN 441774-20-5 CAPLUS
CN Quinoline, 2-methyl-4-[[4-[[[tetrahydro-2-(2-propenyl)-2-furanyl]methyl]thio]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 441774-21-6 CAPLUS
CN Quinoline, 2-methyl-4-[[4-[[[tetrahydro-2-(2-propenyl)-2-furanyl]methyl]sulfonyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 441774-22-7 CAPLUS

CN 2-Furanacetaldehyde, tetrahydro-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441774-23-8 CAPLUS

CN 2-Furanacetic acid, tetrahydro-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441774-24-9 CAPLUS

CN 2-Furanacetic acid, tetrahydro-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-47-6 CAPLUS

CN 3-Oxetaneacetic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-48-7 CAPLUS

CN 3-Oxetaneacetic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonylmethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-52-3 CAPLUS
 CN 2-Pyrrolidinone, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-3-(2-propenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

/
 Me

RN 441774-53-4 CAPLUS
 CN 2-Pyrrolidinone, 1-methyl-3-[[[4-[(2-methyl-4-

quinolinyl)methoxy]phenyl]sulfonyl)methyl]-3-(2-propenyl)- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 2-A

/
Me

RN 441774-54-5 CAPLUS
CN 3-Pyrrolidineacetaldehyde, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

/

Me

RN 441774-55-6 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

/
Me

RN 441774-56-7 CAPLUS
CN 3-Pyrrolidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 441774-75-0 CAPLUS
CN 2H-Pyran-4-acetic acid, tetrahydro-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-76-1 CAPLUS
CN 2H-Pyran-4-acetic acid, tetrahydro-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl)sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:539654 CAPLUS

DOCUMENT NUMBER: 137:93692



TITLE: Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors

INVENTOR(S): Xue, Chu-Biao; Decicco, Carl P.; He, Xiaohua
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company Patent Department, USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055491	A2	20020718	WO 2002-US760	20020109
WO 2002055491	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003087890 A1 20030508 US 2002-43541 20020109
 PRIORITY APPLN. INFO.: US 2001-260957P P 20010111
 OTHER SOURCE(S): MARPAT 137:93692
 GI



AB Title compds. I [wherein A = COR5, CO2H, CH2CO2H, CO2R6, CONHOH, CONHOR5, CONHOR6, N(OH)CHO, N(OH)COR5, SH, CH2SH, SONHRa, SN2H2Ra, PO3H2, or PO(OH)NHRa; ring B = 3-10 membered (hetero)cycle; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl), CO, CO2, OCO, CONH, NHCO, OCO2, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SO0-2, or CO; Za = (un)substituted (hetero)cyclyl; R1a and R1b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR1aR1b = (hetero)cyclyl; R2 = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; R2a = H, alkyl, ORa, (un)substituted CH2NH2, or SO0-2Ra; R2b = H or alkyl; Q =

H or (un)substituted (hetero)cyclyl; R3 = Q1 or (un)substituted alkylene-Q1, alkenylene-Q1, or alkynylene-Q1, Q1-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R3)2 = (un)substituted (hetero)cyclyl; Q1 = H or (un)substituted Ph, naphthyl, or heteroaryl; Ra = H, alkyl, Ph, or PhCH2; p = 0-2; R5 = (un)substituted alkyl; R6 = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepd. as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the 3-(quinolinylmethoxyphenylsulfonylmethyl)-4-piperidinecarboxamide (3R,4S)-II.bul.2CF3CO2H was prepd. in seventeen steps starting from the reaction of N-benzoyloxycarbonyl-.beta.-alanine and benzylbromide. Key steps include the cyclization of the 5-aminopentanal intermediate and the addn. of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline.bul.HCl. A no. of invention compds. exhibited Ki values of .ltoreq. 10 .mu.M against MMP-1, 2, 3, 9, and 13. Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).

IT 441296-96-4P 441297-14-9P 441297-34-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(MMP, TNF, and/or aggrecanase inhibitor; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)

RN 441296-96-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3S,4S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441296-95-3

CMF C29 H35 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 441297-14-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441297-13-8


CMF C29 H35 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 441297-34-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441297-33-2


CMF C28 H33 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 441296-90-8P 441296-93-1P 441296-94-2P
441296-95-3P 441296-97-5P 441296-98-6P
441296-99-7P 441297-00-3P 441297-01-4P
441297-02-5P 441297-03-6P 441297-04-7P
441297-05-8P 441297-06-9P 441297-07-0P
441297-08-1P 441297-09-2P 441297-10-5P
441297-11-6P 441297-12-7P 441297-13-8P

441297-15-0P 441297-16-1P 441297-17-2P
441297-18-3P 441297-19-4P 441297-20-7P
441297-21-8P 441297-22-9P 441297-23-0P
441297-24-1P 441297-25-2P 441297-26-3P
441297-27-4P 441297-28-5P 441297-29-6P
441297-30-9P 441297-31-0P 441297-32-1P
441297-33-2P 441297-35-4P 441297-36-5P
441297-37-6P 441297-38-7P 441297-39-8P
441297-40-1P 441297-47-8P 441297-48-9P
441297-49-0P 441297-50-3P 441297-51-4P
441297-52-5P 441297-53-6P 441297-54-7P
441297-55-8P 441297-56-9P 441297-57-0P
441297-58-1P 441297-59-2P 441297-60-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MMP, TNF, and/or aggrecanase inhibitor; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)

RN 441296-90-8 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441296-89-5

CMF C25 H29 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Me

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441296-93-1 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Pr-i

RN 441296-94-2 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441296-93-1

CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Pr-i

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441296-95-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester,

(3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441296-97-5 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441296-98-6 CAPLUS


CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1 .

CRN 441296-97-5

CMF C24 H27 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441296-99-7 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Me

RN 441297-00-3 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)
CM 1
CRN 441296-99-7
CMF C25 H29 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-01-4 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Pr-i


RN 441297-02-5 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-01-4
CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Pr-i

CM 2

CRN 76-05-1

CMF C2 H F3 O2




.RN 441297-03-6 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-propyl-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Pr-n

RN 441297-04-7 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-propyl-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441297-03-6

CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Pr-n

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-05-8 CAPLUS
CN 4-Piperidinecarboxamide, 1-butyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Bu-n


RN 441297-06-9 CAPLUS
CN 4-Piperidinecarboxamide, 1-butyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-05-8
CMF C28 H35 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Bu-n

CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 441297-07-0 CAPLUS
 CN 4-Piperidinecarboxamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Bu-i


RN 441297-08-1 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-07-0
CMF C28 H35 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Bu-i

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-09-2 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3S,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 441297-10-5 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-09-2

CMF C27 H29 N3 O5 S

Absolute stereochemistry.

1


1



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-11-6 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propenyl)-, (3S,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-12-7 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propenyl)-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-11-6
CMF C27 H31 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-13-8 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-15-0 CAPLUS


CN 3-Piperidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-16-1 CAPLUS
CN 3-Piperidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-15-0
CMF C24 H27 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-17-2 CAPLUS


CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-18-3 CAPLUS
CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-17-2
CMF C25 H29 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-19-4 CAPLUS


CN 3-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-20-7 CAPLUS
CN 3-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-19-4
CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-21-8 CAPLUS

CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-22-9 CAPLUS
CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-21-8
CMF C24 H27 N3 O5 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-23-0 CAPLUS

CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-24-1 CAPLUS


CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-23-0

CMF C25 H29 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-25-2 CAPLUS

CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-26-3 CAPLUS


CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-25-2

CMF C24 H27 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-27-4 CAPLUS

CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-28-5 CAPLUS


CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-27-4

CMF C25 H29 N3 O5 S


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



^/ RN 441297-29-6 CAPLUS ^/
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-30-9 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-29-6
CMF C23 H25 N3 O5 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 441297-31-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-32-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-31-0
CMF C24 H27 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-33-2 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441297-35-4 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-36-5 CAPLUS


CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-35-4

CMF C23 H25 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-37-6 CAPLUS


CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-38-7 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-37-6
CMF C26 H31 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2.

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-39-8 CAPLUS


CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3R,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 441297-40-1 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441297-39-8


CMF C26 H27 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-47-8 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-48-9 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-47-8
CMF C26 H31 N3 O5 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-49-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Me


RN 441297-50-3 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-49-0
CMF C24 H27 N3 O7 S2

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-51-4 CAPLUS

CN 3-Pyrrolidinecarboxamide, 1-(2-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-52-5 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(2-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-51-4
CMF C28 H27 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-53-6 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-54-7 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(3-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-53-6
CMF C28 H27 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-55-8 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-2-furanyl)carbonyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-56-9 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-2-furanyl)carbonyl]- (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-55-8
CMF C28 H31 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-57-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-3-furanyl)carbonyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-58-1 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-3-furanyl)carbonyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-57-0
CMF C28 H31 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-59-2 CAPLUS

CN 3-Pyrrolidinecarboxamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyloxy)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-60-5 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-59-2
CMF C25 H27 N3 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 441297-70-7P 441297-85-4P 441297-86-5P
441297-87-6P 441297-88-7P 441297-89-8P
441297-91-2P 441297-92-3P 441298-02-8P
441298-03-9P 441298-04-0P 441298-05-1P
441298-10-8P 441298-11-9P 441298-12-0P
441298-16-4P 441298-17-5P 441298-19-7P
441298-25-5P 441298-26-6P 441298-27-7P
441298-28-8P 441298-29-9P 441298-33-5P
441298-34-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggreganase inhibitors)

RN 441297-70-7 CAPLUS

CN 4-Piperidinecarboxamide, N,1-dimethyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Me

RN 441297-85-4 CAPLUS
CN 1,4-Piperidinedicarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 1-(1,1-dimethylethyl) 4-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441297-86-5 CAPLUS
CN 1,4-Piperidinedicarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1-(1,1-dimethylethyl) 4-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441297-87-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester, (3R,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 441297-88-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester, (3R,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441297-89-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 441297-91-2 CAPLUS
CN 1,3-Piperidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441297-92-3 CAPLUS
CN 1,3-Piperidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441298-02-8 CAPLUS
CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 3-(1,1-dimethylethyl) 1-(phenylmethyl) ester, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441298-03-9 CAPLUS


CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 3-(1,1-dimethylethyl)-1-(phenylmethyl) ester, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441298-04-0 CAPLUS
CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 3-(1,1-dimethylethyl) 1-(phenylmethyl) ester, (2S,3S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 441298-03-9
CMF C36 H40 N2 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A .



CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 441298-05-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[(methylamino)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, phenylmethyl ester, (2S,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441298-10-8 CAPLUS
CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(1,1-dimethylethyl) ester, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441298-11-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyloxy)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441298-12-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441298-16-4 CAPLUS

CN 1,3-Pyrrolidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(1,1-dimethylethyl) ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441298-17-5 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(1,1-dimethylethyl) ester, (2R,3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441298-16-4
CMF C32 H40 N2 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441298-19-7 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441298-18-6
CMF C28 H34 N2 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441298-25-5 CAPLUS

CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441298-26-6 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441298-27-7 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441298-28-8 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441298-29-9 CAPLUS


CN 3-Pyrrolidinecarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441298-33-5 CAPLUS

CN 3-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Me

RN 441298-34-6 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 1-(2-furanylcarbonyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L8 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:736703 CAPLUS

DOCUMENT NUMBER: 131:336951

TITLE: Preparation of substituted aryl hydroxamic acids as metalloproteinase inhibitors

INVENTOR(S): Xue, Chu-Biao; Decicco, Carl P.; Wexler, Ruth R.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958528	A1	19991118	WO 1999-US10358	19990512
W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2330095	AA	19991118	CA 1999-2330095	19990512
AU 9940747	A1	19991129	AU 1999-40747	19990512
EP 1077974	A1	20010228	EP 1999-924184	19990512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

Searched by Barb O'Bryen, STIC 308-4291

doest reference

SI, LT, LV, FI, RO

JP 2002514644 T2 20020521

JP 2000-548332 19990512

US 6268379 B1 20010731

US 1999-311168 19990513

PRIORITY APPLN. INFO.:

US 1998-85393P P 19980514

WO 1999-US10358 W 19990512

OTHER SOURCE(S): MARPAT 131:336951

GI For diagram(s), see printed CA Issue.

AB Aryl hydroxamic acids I [ring is a 5-8 membered ring contg. 0-2 heteroatoms selected from N, O, and S; Rb = F, Me; X = CH₂CO, CH₂CO₂, CH₂CONH, etc.; Y = OCH₂O, CH₂O, OCHMe, etc.; Z = CH, N; R1 = F, H, Cl, Et, etc.; R2 = F, Cl, Br, I, MeO, etc.; R3 = CHMe₂, F, Cl, CF₃, etc.; R4 = H; R3R4 form a 5-6 membered arom. ring contg. 0-2 heteroatoms; p = 0-2], which are useful as metalloprotease inhibitors (no data), were prepd. E.g., 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide mono(trifluoroacetate) was prepd.

IT 250150-72-2P 250150-73-3P 250150-75-5P

250150-77-7P 250150-78-8P 250150-80-2P

250150-81-3P 250150-83-5P 250150-85-7P

250150-87-9P 250150-88-0P 250150-90-4P


250150-91-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl hydroxamic acids as metalloproteinase inhibitors)

RN 250150-72-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 250150-73-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 250150-72-2


CMF C23 H24 N2 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 250150-75-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 250150-77-7 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 250150-78-8 CAPLUS

CN 4-Piperidinecarboxamide, N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 250150-80-2 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-(methylsulfonyl)-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-81-3 CAPLUS
CN 4-Piperidinecarboxamide, N-hydroxy-1-(methylsulfonyl)-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-83-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-85-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-87-9 CAPLUS
CN 4-Piperidinecarboxamide, 1-(cyclopropylcarbonyl)-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-88-0 CAPLUS
CN 4-Piperidinecarboxamide, 1-(cyclopropylcarbonyl)-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 250150-90-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-cyclopropyl-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 250150-91-5 CAPLUS
CN 4-Piperidinecarboxamide, 1-cyclopropyl-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2003:127675 USPATFULL
TITLE: 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
INVENTOR(S): Xue, Chu-Biao, Hockessin, GERMANY, FEDERAL REPUBLIC OF
Decicco, Carl, Kennett Square, PA, UNITED STATES
He, Xiaohua, Hockessin, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087890	A1	20030508
APPLICATION INFO.:	US 2002-43541	A1	20020109 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-260957P	20010111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3116	

Searched by Barb O'Bryen, STIC 308-4291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes novel 1,2-disubstituted cyclic derivatives of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR.sup.2, and S(O)p and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF-.alpha. inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 441296-96-4P 441297-14-9P 441297-34-3P

(MMP, TNF, and/or aggrecanase inhibitor; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)

RN 441296-96-4 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3S,4S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441296-95-3

CMF C29 H35 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441297-14-9 USPATFULL
CN 1-Piperidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-13-8
CMF C29 H35 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 441297-34-3 USPATFULL

CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441297-33-2


CMF C28 H33 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 441296-90-8P 441296-93-1P 441296-94-2P
441296-95-3P 441296-97-5P 441296-98-6P
441296-99-7P 441297-00-3P 441297-01-4P
441297-02-5P 441297-03-6P 441297-04-7P
441297-05-8P 441297-06-9P 441297-07-0P
441297-08-1P 441297-09-2P 441297-10-5P
441297-11-6P 441297-12-7P 441297-13-8P

441297-15-0P 441297-16-1P 441297-17-2P
441297-18-3P 441297-19-4P 441297-20-7P
441297-21-8P 441297-22-9P 441297-23-0P
441297-24-1P 441297-25-2P 441297-26-3P
441297-27-4P 441297-28-5P 441297-29-6P
441297-30-9P 441297-31-0P 441297-32-1P
441297-33-2P 441297-35-4P 441297-36-5P
441297-37-6P 441297-38-7P 441297-39-8P
441297-40-1P 441297-47-8P 441297-48-9P
441297-49-0P 441297-50-3P 441297-51-4P
441297-52-5P 441297-53-6P 441297-54-7P
441297-55-8P 441297-56-9P 441297-57-0P
441297-58-1P 441297-59-2P 441297-60-5P

(MMP, TNF, and/or aggrecanase inhibitor; prepn. of
(quinolinylmethoxyphenylsulfonylmethyl)-substituted
pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or
aggrecanase inhibitors)

RN 441296-90-8 USPTAFULL

CN 4-Piperidinecarboxamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-,
bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441296-89-5

CMF C25 H29 N3 O5 S

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

Me


CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 441296-93-1 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Pr-i


RN 441296-94-2 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441296-93-1
CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Pr-i

CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 441296-95-3 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441296-97-5 USPTFULL
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441296-98-6 USPATFULL


CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441296-97-5


CMF C24 H27 N3 O5 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441296-99-7 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Me


RN 441297-00-3 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441296-99-7
CMF C25 H29 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441297-01-4 USPATFULL

CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Pr-i


RN 441297-02-5 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1.

CRN 441297-01-4
CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Pr-i

CM 2


CRN 76-05-1
CMF C2¹H F3 O2



RN 441297-03-6 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-propyl-, (3S,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Pr-n


RN 441297-04-7 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-propyl-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-03-6
CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Pr-n

CM 2


CRN 76-05-1
 CMF C2 H F3 O2 11



RN 441297-05-8 USPATFULL
 CN 4-Piperidinecarboxamide, 1-butyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Bu-n


RN 441297-06-9 USPATFULL
CN 4-Piperidinecarboxamide, 1-butyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-05-8
CMF C28 H35 N3 O5 S

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A

Bu-n


CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 441297-07-0 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

Bu-i


RN 441297-08-1 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-07-0
CMF C28 H35 N3 O5 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


Bu-i

CM 2

CRN 76-05-1
 /CMF C2 H F3 O2


/

/



RN 441297-09-2 USPATFULL
 CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-10-5 USPATFULL


CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-09-2


CMF C27 H29 N3 O5 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-11-6 \ USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propenyl)-, (3S,4S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-12-7 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propenyl)-, (3S,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-11-6
CMF C27 H31 N3 O5 S

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 441297-13-8 USPATFULL
CN 1-Piperidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441297-15-0 USPATFULL
CN 3-Piperidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-16-1 USPATFULL
CN 3-Piperidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-15-0
CMF C24 H27 N3 O5 S

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 441297-17-2 USPATFULL
CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-18-3 USPATFULL
CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-17-2
CMF C25 H29 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-19-4 USPATFULL


CN 3-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-20-7 USPATFULL
CN 3-Piperidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4R)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-19-4
CMF C27 H33 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
 CMF. C2 H F3 O2



RN 441297-21-8 USPATFULL
 CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-22-9 USPATFULL


CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-21-8

CMF C24 H27 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-23-0 USPATFULL

CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-24-1 USPATFULL


CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2S,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-23-0

CMF C25 H29 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-25-2 USPATFULL

CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-26-3 USPATFULL
CN 3-Piperidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-25-2
CMF C24 H27 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-27-4 USPATFULL

CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-28-5 USPATFULL


CN 3-Piperidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-27-4

CMF C25 H29 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441297-29-6 USPATFULL

CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-30-9 USPATFULL


CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-29-6


CMF C23 H25 N3 O5 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 441297-31-0 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-32-1 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-31-0
CMF C24 H27 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-33-2 USPATFULL


CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441297-35-4 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-36-5 USPATFULL


CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-35-4

CMF C23 H25 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-37-6 USPATFULL


CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




11
RN 441297-38-7 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-37-6
CMF C26 H31 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 441297-39-8 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-40-1 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, (3R,4S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441297-39-8
CMF C26 H27 N3 O5 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 441297-47-8 USPATFULL
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-48-9 USPTAFULL


CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-47-8


CMF C26 H31 N3 O5 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-49-0 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, (2R,3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-50-3 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-49-0
CMF C24 H27 N3 O7 S2

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Me

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 441297-51-4 USPATFULL
CN 3-Pyrrolidinecarboxamide, 1-(2-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-52-5 USPATFULL
CN 3-Pyrrolidinecarboxamide, 1-(2-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-51-4
CMF C28 H27 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-53-6 USPATFULL

CN 3-Pyrrolidinecarboxamide, 1-(3-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-54-7 USPATFULL
CN 3-Pyrrolidinecarboxamide, 1-(3-furanylcarbonyl)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-53-6
CMF C28 H27 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-55-8 USPATFULL

CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-2-furanyl)carbonyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-56-9 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-2-furanyl)carbonyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-55-8
CMF C28 H31 N3 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441297-57-0 USPATFULL

CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-3-furanyl)carbonyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441297-58-1 USPATFULL
CN 3-Pyrrolidinecarboxamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-[(tetrahydro-3-furanyl)carbonyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-57-0
CMF C28 H31 N3 O7 S

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 441297-59-2 USPATFULL
CN 3-Pyrrolidinecarboxamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441297-60-5 USPATFULL


CN 3-Pyrrolidinecarboxamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinoliny)methoxy]phenyl]sulfonyl]methyl]-, (2R,3S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441297-59-2


CMF C25 H27 N3 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 441297-70-7P 441297-85-4P 441297-86-5P
441297-87-6P 441297-88-7P 441297-89-8P
441297-91-2P 441297-92-3P 441298-02-8P
441298-03-9P 441298-04-0P 441298-05-1P
441298-10-8P 441298-11-9P 441298-12-0P
441298-16-4P 441298-17-5P 441298-19-7P
441298-25-5P 441298-26-6P 441298-27-7P
441298-28-8P 441298-29-9P 441298-33-5P
441298-34-6P


(intermediate; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-
substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP,
TNF, and/or aggrecanase inhibitors)

RN 441297-70-7 USPTFULL

CN. 4-Piperidinecarboxamide, N,1-dimethyl-3-[[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441297-85-4 USPATFULL
 CN 1,4-Piperidinedicarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 1-(1,1-dimethylethyl) 4-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441297-86-5 USPATFULL
 CN 1,4-Piperidinedicarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1-(1,1-dimethylethyl) 4-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441297-87-6 USPATFULL
CN 4-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester, (3R,4S)-
/ (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441297-88-7 USPATFULL

CN 4-Piperidinecarboxylic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester, (3R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Me

RN 441297-89-8 USPATFULL
CN 4-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 441297-91-2 USPATFULL
CN 1,3-Piperidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441297-92-3 USPATFULL
CN 1,3-Piperidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441298-02-8 USPATFULL

CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 3-(1,1-dimethylethyl) 1-(phenylmethyl) ester, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441298-03-9 USPATFULL


CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 3-(1,1-dimethylethyl)-1-(phenylmethyl) ester, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 441298-04-0 USPATFULL
CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 3-(1,1-dimethylethyl) 1-(phenylmethyl) ester, (2S,3S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 441298-03-9


CMF C36 H40 N2 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 441298-05-1 USPATFULL
CN 1-Piperidinecarboxylic acid, 3-[(methylamino)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, phenylmethyl ester, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441298-10-8 USPATFULL
CN 1,3-Piperidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(1,1-dimethylethyl) ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441298-11-9 USPATFULL
CN 3-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 441298-12-0 USPATFULL

CN 3-Piperidinecarboxylic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441298-16-4 USPATFULL

CN 1,3-Pyrrolidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(1,1-dimethylethyl) ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441298-17-5 USPATFULL
CN 1,3-Pyrrolidinedicarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(1,1-dimethylethyl) ester, (2R,3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441298-16-4
CMF C32 H40 N2 O7 S

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 441298-19-7 USPATFULL


CN 3-Pyrrolidinecarboxylic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441298-18-6

CMF C28 H34 N2 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441298-25-5 USPATFULL

CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 441298-26-6 USPATFULL
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1-(1,1-dimethylethyl) 3-methyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 441298-27-7 USPATFULL
CN 3-Pyrrolidinecarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R, 4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 441298-28-8 USPATFULL


CN 3-Pyrrolidinecarboxylic acid, 1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441298-29-9 USPATFULL


CN 3-Pyrrolidinecarboxylic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propynyl)-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 441298-33-5 USPATFULL

CN 3-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

Me

RN 441298-34-6 USPATFULL
CN 3-Pyrrolidinecarboxylic acid, 1-(2-furanylcarbonyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

||
O

L8 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:251781 USPATFULL

TITLE: 1,1-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha

INVENTOR(S): Chen, Xiao-Tao, Newark, DE, UNITED STATES
Xue, Chu-Biao, Hockessin, DE, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137734	A1	20020926
APPLICATION INFO.:	US 2002-43627	A1	20020109 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-260952P	20010111 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BRISTOL-MYERS SQUIBB PHARMA COMPANY, PATENT DEPARTMENT, P.O. BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3545	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes novel 1,1-disubstituted cyclic derivatives of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR^{sup.2}, S, S(O), and S(O)₂ and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF- α inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 441772-86-7P 441772-87-8P 441772-88-9P

441772-89-0P 441772-90-3P 441772-91-4P

441772-92-5P 441772-93-6P 441772-94-7P

441772-95-8P 441772-96-9P 441772-97-0P

441772-98-1P 441772-99-2P 441773-00-8P

441773-01-9P 441773-02-0P 441773-03-1P

441773-04-2P 441773-05-3P 441773-06-4P

441773-07-5P 441773-08-6P 441773-09-7P

441773-11-1P 441773-12-2P 441773-13-3P

441773-14-4P 441773-15-5P 441773-16-6P

441773-17-7P 441773-18-8P 441773-19-9P

441773-20-2P 441773-21-3P 441773-22-4P

441773-23-5P 441773-24-6P 441773-25-7P

441773-26-8P 441773-27-9P 441773-28-0P

441773-29-1P 441773-30-4P 441773-31-5P

441773-42-8P 441773-43-9P 441773-44-0P


441773-45-1P 441773-52-0P 441773-53-1P

441773-54-2P

(MMP, TNF, and/or aggrecanase inhibitor; prepn. of
(quinolinylmethoxyphenylsulfonylmethyl)-substituted
pyrrolidineacetamides and piperidineacetamides and related compds. as
MMP, TNF, and/or aggrecanase inhibitors)

RN 441772-86-7 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441772-87-8 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate)
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-86-7


CMF C24 H27 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-88-9 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441772-89-0 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-88-9


CMF C25 H29 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-90-3 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441772-91-4 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-90-3


CMF C28 H35 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-92-5 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 441772-93-6 USPATFULL

CN 2-Pyrrolidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-92-5


CMF C29 H30 N4 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-94-7 USPATFULL

CN 2-Pyrrolidineacetamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441772-95-8 USPATFULL

CN 2-Pyrrolidineacetamide, 1-acetyl-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-94-7


CMF C26 H29 N3 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441772-96-9 USPATFULL

CN 3-Pyrrolidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA. INDEX NAME)




RN 441772-97-0 USPATFULL

CN 3-Pyrrolidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyloxy)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441772-96-9

CMF C24 H27 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 441772-98-1 USPATFULL
CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

/


Me

RN 441772-99-2 USPATFULL
CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441772-98-1
CMF C25 H29 N3 O5 S

PAGE 1-A



PAGE 2-A


/

Me

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-00-8 USPATFULL

CN 3-Pyrrolidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


/
i-Pr

RN 441773-01-9 USPATFULL
CN 3-Pyrrolidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate)
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-00-8
CMF C27 H33 N3 O5 S

PAGE 1-A



PAGE 2-A


/

i-Pr

CM 2

CRN 76-05-1


CMF C2 H. F3 O2



RN 441773-02-0 USPATFULL

CN 3-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

/


i-Bu

RN 441773-03-1 USPATFULL
CN 3-Pyrrolidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate)
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-02-0
CMF C28 H35 N3 O5 S

PAGE 1-A



PAGE 2-A


/

i-Bu

CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 441773-04-2 USPATFULL

CN 3-Pyrrolidineacetamide, 1-(2,2-dimethylpropyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 441773-05-3 USPATFULL
 CN 3-Pyrrolidineacetamide, 1-(2,2-dimethylpropyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 441773-04-2
 CMF C29 H37 N3 O5 S


PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 441773-06-4 USPATFULL
CN 2-Piperidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-07-5 USPATFULL

CN 2-Piperidineacetamide, N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-06-4

CMF C25 H29 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-08-6 USPATFULL
CN 2-Piperidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-09-7 USPATFULL
CN 2-Piperidineacetamide, N-hydroxy-1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-08-6
CMF C26 H31 N3 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 441773-11-1 USPATFULL

CN 2-Piperidineacetamide, N-hydroxy-1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate)
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-10-0


CMF C29 H37 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-12-2 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-13-3 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1.


CRN 441773-12-2

CMF C25 H29 N3 O4 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-14-4 USPATFULL
CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-15-5 USPATFULL
CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-14-4
CMF C26 H31 N3 O4 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 441773-16-6 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-17-7 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinoliny) methoxy] phenyl] sulfinyl] methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-16-6

CMF C28 H35 N3 O4 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-18-8 USPATFULL
CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-19-9 USPATFULL
CN 3-Piperidineacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-18-8
CMF C25 H29 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-20-2 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-21-3 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-20-2

CMF C26 H31 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-22-4 USPATFULL
CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-23-5 USPATFULL
CN 3-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-22-4
CMF C28 H35 N3 O5 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-24-6 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-25-7 USPATFULL

CN 3-Piperidineacetamide, N-hydroxy-1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-24-6

CMF C29 H37 N3 O5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-26-8 USPATFULL
CN 4-Piperidineacetamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-27-9 USPATFULL
CN 4-Piperidineacetamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-26-8
CMF C25 H29 N3 O5 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-28-0 USPATFULL

CN 4-Piperidineacetamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 441773-29-1 USPATFULL
CN 4-Piperidineacetamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate)
(salt) (9CI) (CA INDEX NAME)
CM 1

CRN 441773-28-0
CMF C26 H31 N3 O5 S

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 441773-30-4 USPATFULL
CN 2-Furanacetamide, tetrahydro-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-31-5 USPATFULL

CN 2-Furanacetamide, tetrahydro-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-30-4


CMF C24 H26 N2 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 441773-42-8 USPATFULL

CN 3-Oxetaneacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-43-9 USPATFULL

CN 3-Oxetaneacetamide, N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-42-8


CMF C23 H24 N2 O6 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-44-0 USPATFULL

CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

/
 Me

RN 441773-45-1 USPATFULL


CN 3-Pyrrolidineacetamide, N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-44-0

CMF C25 H27 N3 O6 S


PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 441773-52-0 USPATFULL
CN 2H-Pyran-4-acetamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-53-1 USPATFULL

CN 2H-Pyran-4-acetamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 441773-52-0

CMF C25 H28 N2 O6 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 441773-54-2 USPATFULL
CN 2-Piperidineacetamide, N-hydroxy-1-(1-methylethyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




IT 441773-57-5P 441773-58-6P 441773-59-7P
441773-60-0P 441773-61-1P 441773-62-2P
441773-63-3P 441773-64-4P 441773-65-5P
441773-66-6P 441773-74-6P 441773-75-7P
441773-77-9P 441773-79-1P 441773-80-4P
441773-81-5P 441773-85-9P 441773-86-0P
441773-87-1P 441773-88-2P 441773-89-3P
441773-90-6P 441773-91-7P 441773-92-8P
441773-96-2P 441773-97-3P 441773-98-4P
441773-99-5P 441774-00-1P 441774-01-2P
441774-02-3P 441774-03-4P 441774-04-5P
441774-05-6P 441774-06-7P 441774-08-9P
441774-13-6P 441774-14-7P 441774-15-8P
441774-16-9P 441774-20-5P 441774-21-6P
441774-22-7P 441774-23-8P 441774-24-9P
441774-47-6P 441774-48-7P 441774-52-3P
441774-53-4P 441774-54-5P 441774-55-6P
441774-56-7P 441774-75-0P 441774-76-1P
(intermediate; prepn. of (quinolinylmethoxyphenylsulfonylmethyl)-
substituted pyrrolidineacetamides and piperidineacetamides and related
compds. as MMP, TNF, and/or aggrecanase inhibitors)
RN 441773-57-5 USPATFULL
CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-2-(2-propenyl)-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-58-6 USPATFULL

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-59-7 USPATFULL

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-60-0 USPATFULL

CN 2-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441773-61-1 USPATFULL

CN 2-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-62-2 USPATFULL

CN 2-Pyrrolidineacetic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-63-3 USPATFULL

CN 2-Pyrrolidineacetic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-64-4 USPATFULL

CN 2-Pyrrolidineacetic acid, 1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-65-5 USPATFULL

CN 2-Pyrrolidineacetic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 441773-66-6 USPATFULL


CN 2-Pyrrolidineacetic acid, 1-acetyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-74-6 USPATFULL

CN 3-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-75-7 USPATFULL
CN 3-Pyrrolidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 441773-77-9 USPATFULL
CN 3-Pyrrolidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-76-8
CMF C27 H32 N2 O5 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 441773-79-1 USPATFULL


CN 3-Pyrrolidineacetic acid, 1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 441773-78-0

CMF C29 H36 N2 O5 S

PAGE 1-A



PAGE 2-A


/

i-Pr

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 441773-80-4 USPATFULL

CN 3-Pyrrolidineacetic acid, 1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


i-Bu

RN 441773-81-5 USPATFULL
CN 3-Pyrrolidineacetic acid, 1-(2,2-dimethylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 441773-85-9 USPATFULL
CN Quinoline, 2-methyl-4-[[[4-[[[2-(2-propenyl)-2-piperidinyl]methyl]thio]phenoxy]methyl]]- (9CI) (CA INDEX NAME)




RN 441773-86-0 USPATFULL

CN 1-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-2-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-87-1 USPATFULL

CN 1-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-88-2 USPATFULL

CN 1-Piperidinecarboxylic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-(2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 441773-89-3 USPATFULL

CN 2-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 441773-90-6 USPATFULL


CN 2-Piperidineacetic acid, 2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 441773-91-7 USPATFULL

CN 2-Piperidineacetic acid, 1-methyl-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441773-92-8 USPATFULL


CN 2-Piperidineacetic acid, 1-(2-methylpropyl)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441773-96-2 USPATFULL

CN 1-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-3-(2-propenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-97-3 USPATFULL
CN 1-Piperidinecarboxylic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-3-(2-oxoethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-98-4 USPATFULL
CN 3-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441773-99-5 USPATFULL
CN 3-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 441774-00-1 USPATFULL
CN 3-Piperidineacetic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-01-2 USPATFULL

CN 3-Piperidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-02-3 USPATFULL


CN 3-Piperidineacetic acid, 1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-03-4 USPATFULL

CN 3-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441774-04-5 USPATFULL

CN 3-Piperidineacetic acid, 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-05-6 USPATFULL

CN 3-Piperidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-06-7 USPATFULL

CN 3-Piperidineacetic acid, 1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-08-9 USPATFULL


CN 3-Piperidineacetic acid, 1-(2-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-13-6 USPATFULL

CN 4-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 441774-14-7 USPATFULL

CN 4-Piperidineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 441774-15-8 USPATFULL


CN 4-Piperidineacetic acid, 4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-16-9 USPATFULL

CN 4-Piperidineacetic acid, 1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
Me


RN 441774-20-5 USPATFULL

CN Quinoline, 2-methyl-4-[[4-[[[tetrahydro-2-(2-propenyl)-2-furanyl]methyl]thio]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 441774-21-6 USPATFULL

CN Quinoline, 2-methyl-4-[[4-[[[tetrahydro-2-(2-propenyl)-2-furanyl]methyl]sulfonyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 441774-22-7 USPATFULL

CN 2-Furanacetaldehyde, tetrahydro-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441774-23-8 USPATFULL

CN 2-Furanacetic acid, tetrahydro-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 441774-24-9 USPATFULL

CN 2-Furanacetic acid, tetrahydro-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441774-47-6 USPATFULL

CN 3-Oxetaneacetic acid; 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-48-7 USPATFULL


CN 3-Oxetaneacetic acid; 3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-52-3 USPATFULL

CN 2-Pyrrolidinone, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-3-(2-propenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

/


Me

RN 441774-53-4 USPATFULL

CN 2-Pyrrolidinone, 1-methyl-3-[[[4-[(2-methyl-4-

quinolinyl)methoxy]phenyl]sulfonyl)methyl]-3-(2-propenyl)- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 2-A

/

Me

RN 441774-54-5 USPATFULL
CN 3-Pyrrolidineacetaldehyde, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl)methyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

/
Me

RN 441774-55-6 USPATFULL
CN 3-Pyrrolidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

/
Me

RN 441774-56-7 USPATFULL
CN 3-Pyrrolidineacetic acid, 1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-2-oxo-, methyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A

/


Me

RN 441774-75-0 USPATFULL
CN 2H-Pyran-4-acetic acid, tetrahydro-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]thio]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 441774-76-1 USPTFULL

CN 2H-Pyran-4-acetic acid, tetrahydro-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 6 USPTFULL on STN

ACCESSION NUMBER: 2001:121486 USPTFULL

TITLE: Substituted aryl hydroxamic acids as metalloproteinase inhibitors

INVENTOR(S):
 Xue, Chu-Biao, Hockessin, DE, United States
 Decicco, Carl P., Newark, DE, United States
 Wexler, Ruth R., Wilmington, DE, United States

Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6268379	B1	20010731
APPLICATION INFO.:	US 1999-311168		19990513 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-85393P	19980514 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davis, Zinna Northington	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1496	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes novel substituted aryl hydroxamic acids of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-2 heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 250150-72-2P 250150-73-3P 250150-75-5P
250150-77-7P 250150-78-8P 250150-80-2P
250150-81-3P 250150-83-5P 250150-85-7P
250150-87-9P 250150-88-0P 250150-90-4P
250150-91-5P

(prepn. of aryl hydroxamic acids as metalloproteinase inhibitors)

RN 250150-72-2 USPATFULL

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 250150-73-3 USPATFULL


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-

quinolinylmethoxy)phenyl]sulfonylmethyl]-, mono(trifluoroacetate)
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 250150-72-2


CMF C23 H24 N2 O6 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 250150-75-5 USPATFULL

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonylmethyl]- (9CI) (CA INDEX NAME)




RN 250150-77-7 USPATFULL

CN 4-Piperidinecarboxamide, N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonylmethyl]- (9CI) (CA INDEX NAME)



RN 250150-78-8 USPATFULL


CN 4-Piperidinecarboxamide, N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonylmethyl]- (9CI) (CA INDEX NAME)




RN 250150-80-2 USPATFULL

CN 4-Piperidinecarboxamide, N-hydroxy-1-(methylsulfonyl)-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-81-3 USPATFULL
CN 4-Piperidinecarboxamide, N-hydroxy-1-(methylsulfonyl)-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-83-5 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-85-7 USPATFULL
CN 1-Piperidinecarboxylic acid, 4-[(hydroxyamino)carbonyl]-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-87-9 USPATFULL
CN 4-Piperidinecarboxamide, 1-(cyclopropylcarbonyl)-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 250150-88-0 USPATFULL
CN 4-Piperidinecarboxamide, 1-(cyclopropylcarbonyl)-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 250150-90-4 USPATFULL
CN 4-Piperidinecarboxamide, 1-cyclopropyl-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 250150-91-5 USPATFULL
CN 4-Piperidinecarboxamide, 1-cyclopropyl-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



FILE 'CAOLD' ENTERED AT 14:51:25 ON 14 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L1 STR
L2 STR
L4 212 SEA FILE=REGISTRY SSS FUL L1 AND L2

Searched by Barb O'Bryen, STIC 308-4291

L7

0 SEA FILE=CAOLD ABB=ON L4

FILE 'HOME' ENTERED AT 14:51:25 ON 14 AUG 2003

THIS PAGE BLANK (USPTO)